Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Academic Medical Centers | 6 | 2011 | 309 | 0.700 |
Why?
|
| Quality Assurance, Health Care | 4 | 2009 | 253 | 0.570 |
Why?
|
| Cooperative Behavior | 2 | 2011 | 230 | 0.500 |
Why?
|
| Quality Indicators, Health Care | 2 | 2009 | 348 | 0.450 |
Why?
|
| Leadership | 2 | 2011 | 214 | 0.350 |
Why?
|
| Hospitals, University | 1 | 2011 | 57 | 0.340 |
Why?
|
| Diagnosis-Related Groups | 1 | 2011 | 86 | 0.340 |
Why?
|
| Schools, Medical | 1 | 2011 | 150 | 0.320 |
Why?
|
| Safety Management | 2 | 2010 | 139 | 0.310 |
Why?
|
| Respiration, Artificial | 2 | 2006 | 300 | 0.300 |
Why?
|
| Neurosurgical Procedures | 1 | 2010 | 105 | 0.290 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2010 | 272 | 0.240 |
Why?
|
| Hospital Mortality | 1 | 2010 | 879 | 0.220 |
Why?
|
| Survivors | 1 | 2006 | 187 | 0.210 |
Why?
|
| Evidence-Based Medicine | 1 | 2006 | 464 | 0.200 |
Why?
|
| United States | 9 | 2011 | 8166 | 0.190 |
Why?
|
| Quality of Health Care | 3 | 2010 | 533 | 0.150 |
Why?
|
| Intensive Care Units | 2 | 2006 | 436 | 0.140 |
Why?
|
| Thermometers | 1 | 1996 | 3 | 0.120 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 1996 | 7 | 0.120 |
Why?
|
| Pneumonia, Bacterial | 1 | 1997 | 91 | 0.120 |
Why?
|
| Cross Infection | 1 | 1997 | 170 | 0.110 |
Why?
|
| Ambulatory Care | 2 | 2009 | 318 | 0.110 |
Why?
|
| Humans | 16 | 2011 | 65645 | 0.090 |
Why?
|
| Bronchial Fistula | 1 | 1992 | 4 | 0.090 |
Why?
|
| Cellulitis | 1 | 1992 | 16 | 0.090 |
Why?
|
| Fistula | 1 | 1992 | 17 | 0.090 |
Why?
|
| Pneumococcal Infections | 1 | 1992 | 39 | 0.090 |
Why?
|
| Direct Service Costs | 1 | 2011 | 3 | 0.090 |
Why?
|
| Financing, Government | 1 | 2011 | 31 | 0.080 |
Why?
|
| Skin Diseases | 1 | 1992 | 80 | 0.080 |
Why?
|
| Hospital Costs | 1 | 2011 | 126 | 0.080 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2010 | 27 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 105 | 0.070 |
Why?
|
| Heparin | 1 | 2010 | 120 | 0.070 |
Why?
|
| Patient Care | 1 | 2009 | 79 | 0.070 |
Why?
|
| Trauma Centers | 1 | 2010 | 130 | 0.070 |
Why?
|
| Medication Errors | 1 | 2010 | 127 | 0.070 |
Why?
|
| Risk Adjustment | 1 | 2009 | 94 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2010 | 309 | 0.070 |
Why?
|
| Coronary Artery Bypass | 1 | 2010 | 292 | 0.070 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2010 | 171 | 0.070 |
Why?
|
| Organizational Objectives | 1 | 2007 | 59 | 0.070 |
Why?
|
| Organizational Innovation | 1 | 2007 | 85 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1116 | 0.060 |
Why?
|
| Faculty, Medical | 2 | 2009 | 200 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2010 | 888 | 0.060 |
Why?
|
| General Surgery | 1 | 2009 | 210 | 0.060 |
Why?
|
| Health Services Research | 1 | 2007 | 265 | 0.060 |
Why?
|
| Medical Audit | 1 | 2006 | 67 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2010 | 529 | 0.060 |
Why?
|
| Organizational Affiliation | 1 | 2005 | 6 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 2789 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2009 | 731 | 0.050 |
Why?
|
| Risk Factors | 2 | 2010 | 5466 | 0.050 |
Why?
|
| Benchmarking | 1 | 2005 | 137 | 0.050 |
Why?
|
| Information Dissemination | 1 | 2005 | 114 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2010 | 2113 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2006 | 5656 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2009 | 802 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 741 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 1163 | 0.040 |
Why?
|
| Databases as Topic | 2 | 2010 | 49 | 0.040 |
Why?
|
| Aged | 3 | 2006 | 15089 | 0.040 |
Why?
|
| Electric Wiring | 1 | 1997 | 1 | 0.030 |
Why?
|
| Tobramycin | 1 | 1997 | 6 | 0.030 |
Why?
|
| Ampicillin | 1 | 1997 | 12 | 0.030 |
Why?
|
| Penicillins | 1 | 1997 | 32 | 0.030 |
Why?
|
| Gentamicins | 1 | 1997 | 24 | 0.030 |
Why?
|
| Nurseries, Hospital | 1 | 1996 | 2 | 0.030 |
Why?
|
| Hepatitis B Core Antigens | 1 | 1996 | 5 | 0.030 |
Why?
|
| Equipment Safety | 1 | 1996 | 29 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 1996 | 9 | 0.030 |
Why?
|
| Burns | 1 | 1996 | 46 | 0.030 |
Why?
|
| Adult | 3 | 2006 | 17511 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 1996 | 267 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1997 | 318 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 1997 | 463 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 1996 | 104 | 0.030 |
Why?
|
| Equipment Design | 1 | 1996 | 373 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 1997 | 1437 | 0.030 |
Why?
|
| Middle Aged | 2 | 2006 | 18439 | 0.030 |
Why?
|
| Time Factors | 2 | 1997 | 3777 | 0.020 |
Why?
|
| Incidence | 1 | 1996 | 1432 | 0.020 |
Why?
|
| Lung Abscess | 1 | 1992 | 6 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1997 | 807 | 0.020 |
Why?
|
| Pennsylvania | 1 | 2010 | 66 | 0.020 |
Why?
|
| Cohort Studies | 1 | 1996 | 2639 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2010 | 48 | 0.020 |
Why?
|
| Ohio | 1 | 2009 | 24 | 0.020 |
Why?
|
| HIV Infections | 1 | 1996 | 958 | 0.020 |
Why?
|
| Safety | 1 | 2009 | 142 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2009 | 111 | 0.020 |
Why?
|
| Curriculum | 1 | 2009 | 609 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2009 | 762 | 0.010 |
Why?
|
| Female | 3 | 1997 | 34309 | 0.010 |
Why?
|
| Male | 2 | 1997 | 31292 | 0.010 |
Why?
|
| Fetal Blood | 1 | 1997 | 73 | 0.010 |
Why?
|
| Epidemiologic Factors | 1 | 1996 | 4 | 0.010 |
Why?
|
| Culture Media | 1 | 1997 | 78 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1997 | 126 | 0.010 |
Why?
|
| Carrier State | 1 | 1996 | 20 | 0.010 |
Why?
|
| Hepatitis B | 1 | 1996 | 28 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1996 | 140 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1997 | 491 | 0.010 |
Why?
|
| Temperature | 1 | 1997 | 317 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1997 | 858 | 0.010 |
Why?
|
| Massachusetts | 1 | 1996 | 2154 | 0.000 |
Why?
|